186 related articles for article (PubMed ID: 27332712)
1. Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats.
Curtis RC; Custis JT; Ehrhart NP; Ehrhart EJ; Condon KW; Gookin SE; Donahue SW
PLoS One; 2016; 11(6):e0158005. PubMed ID: 27332712
[TBL] [Abstract][Full Text] [Related]
2. Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy.
Arrington SA; Fisher ER; Willick GE; Mann KA; Allen MJ
Calcif Tissue Int; 2010 Sep; 87(3):263-72. PubMed ID: 20563797
[TBL] [Abstract][Full Text] [Related]
3. The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.
Li YF; Zhou CC; Li JH; Luo E; Zhu SS; Feng G; Hu J
Osteoporos Int; 2012 Apr; 23(4):1463-74. PubMed ID: 21892678
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined treatment with zoledronic acid and parathyroid hormone on mouse bone callus structure and composition.
Casanova M; Herelle J; Thomas M; Softley R; Schindeler A; Little D; Schneider P; Müller R
Bone; 2016 Nov; 92():70-78. PubMed ID: 27542660
[TBL] [Abstract][Full Text] [Related]
5. PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology.
Bartlow CM; Oest ME; Mann KA; Zimmerman ND; Butt BB; Damron TA
J Orthop Res; 2017 Aug; 35(8):1707-1715. PubMed ID: 27653318
[TBL] [Abstract][Full Text] [Related]
6. Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface.
Li YF; Li XD; Bao CY; Chen QM; Zhang H; Hu J
Osteoporos Int; 2013 Mar; 24(3):1063-71. PubMed ID: 23296744
[TBL] [Abstract][Full Text] [Related]
7. Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT.
Hansen S; Hauge EM; Beck Jensen JE; Brixen K
J Bone Miner Res; 2013 Apr; 28(4):736-45. PubMed ID: 23044908
[TBL] [Abstract][Full Text] [Related]
8. Orthotopic model of canine osteosarcoma in athymic rats for evaluation of stereotactic radiotherapy.
Schwartz AL; Custis JT; Harmon JF; Powers BE; Chubb LS; LaRue SM; Ehrhart NP; Ryan SD
Am J Vet Res; 2013 Mar; 74(3):452-8. PubMed ID: 23438123
[TBL] [Abstract][Full Text] [Related]
9. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.
Vegger JB; Nielsen ES; Brüel A; Thomsen JS
Bone; 2014 Sep; 66():287-95. PubMed ID: 24970039
[TBL] [Abstract][Full Text] [Related]
10. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats.
Little DG; Peat RA; Mcevoy A; Williams PR; Smith EJ; Baldock PA
J Bone Miner Res; 2003 Nov; 18(11):2016-22. PubMed ID: 14606515
[TBL] [Abstract][Full Text] [Related]
13. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.
Amanat N; McDonald M; Godfrey C; Bilston L; Little D
J Bone Miner Res; 2007 Jun; 22(6):867-76. PubMed ID: 17371160
[TBL] [Abstract][Full Text] [Related]
14. Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model.
Doi Y; Miyazaki M; Yoshiiwa T; Hara K; Kataoka M; Tsumura H
Bone; 2011 Oct; 49(4):777-82. PubMed ID: 21777711
[TBL] [Abstract][Full Text] [Related]
15. Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone.
Kuroshima S; Elliott KW; Yamashita J
Calcif Tissue Int; 2013 Jun; 92(6):576-85. PubMed ID: 23503790
[TBL] [Abstract][Full Text] [Related]
16. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis.
Arrington SA; Damron TA; Mann KA; Allen MJ
J Surg Oncol; 2008 Mar; 97(3):284-90. PubMed ID: 18161868
[TBL] [Abstract][Full Text] [Related]
17. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid.
Hui SK; Fairchild GR; Kidder LS; Sharma M; Bhattacharya M; Jackson S; Le C; Yee D
Calcif Tissue Int; 2012 Jan; 90(1):40-9. PubMed ID: 22083107
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid Hormone (1-34) Transiently Protects Against Radiation-Induced Bone Fragility.
Oest ME; Mann KA; Zimmerman ND; Damron TA
Calcif Tissue Int; 2016 Jun; 98(6):619-30. PubMed ID: 26847434
[TBL] [Abstract][Full Text] [Related]
19. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
20. Systemic but no local effects of combined zoledronate and parathyroid hormone treatment in experimental autoimmune arthritis.
Keller KK; Thomsen JS; Stengaard-Pedersen K; Hauge EM
PLoS One; 2014; 9(3):e92359. PubMed ID: 24637846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
